

Table S3 Results of the candidate gene analysis with *SLCO1B1* haplotypes on 3R,5S- and 3S,5R-fluvastatin AUC_{0-∞}, total fluvastatin AUC_{0-∞}, and 3R,5S/3S,5R AUC_{0-∞} ratio.

Pharmacokinetic variable	Covariate/SNV	Effect*			Bonferroni adjusted <i>P</i> value	Adjusted R ² for each step
		Average	90% CI	<i>P</i> value		
3R,5S-fluvastatin AUC _{0-∞}	BSA	-19.7%	-23.2%, 16.0%	4.32 × 10 ⁻¹⁴		0.24
	<i>CYP2C9</i> *3 (rs1057910)	64.8%	43.8%, 88.9%	6.92 × 10 ⁻⁹	2.01 × 10 ⁻⁷	0.36
	<i>SLCO1B1</i> *15	36.2%	24.6%, 49.1%	4.57 × 10 ⁻⁸	1.33 × 10 ⁻⁶	0.45
	<i>CYP2C9</i> *2 (rs17999853)	21.2%	8.8%, 35.0%	0.00360	0.104	0.47
3S,5R-fluvastatin AUC _{0-∞}	BSA	-20.7%	-24.4%, -16.8%	9.14 × 10 ⁻¹⁴		0.20
	<i>CYP2C9</i> *3 (rs1057910)	93.6%	67.2%, 124.2%	2.80 × 10 ⁻¹²	7.85 × 10 ⁻¹¹	0.35
	<i>CYP2C9</i> *2 (rs17999853)	29.1%	14.9%, 45.0%	3.81 × 10 ⁻⁴	0.0107	0.38
	<i>SLCO2B1</i> c.601G>A (rs35199625)	45.2%	10.7%, 90.6%	0.0242	0.679	0.39
	<i>SLCO2B1</i> c.1457C>T (rs2306168)	-21.7%	-34.9%, -5.8%	0.0301	0.844	0.40
Total AUC _{0-∞}	BSA	-19.6%	-23.2%, -15.8%	2.00 × 10 ⁻¹³		0.23
	<i>CYP2C9</i> *3 (rs1057910)	73.8%	51.1%, 99.8%	5.27 × 10 ⁻¹⁰	1.53 × 10 ⁻⁸	0.37
	<i>SLCO1B1</i> *15	23.0%	12.2%, 34.9%	2.59 × 10 ⁻⁴	0.00750	0.40
	<i>CYP2C9</i> *2 (rs17999853)	24.4%	11.5%, 39.0%	0.00124	0.0359	0.43
3R,5S/3S,5R AUC _{0-∞} ratio	<i>SLCO1B1</i> *15	25.0%	21.2%, 28.9%	3.30 × 10 ⁻²⁵	9.58 × 10 ⁻²⁴	0.33
	<i>SLCO1B1</i> *35	-15.7%	-20.4%, -10.8%	1.85 × 10 ⁻⁶	5.36 × 10 ⁻⁵	0.39
	<i>SLCO1B1</i> *5	26.6%	17.7%, 36.1%	2.44 × 10 ⁻⁷	7.07 × 10 ⁻⁶	0.45
	<i>SLCO1B1</i> *14	-10.0%	-13.9%, -5.9%	1.08 × 10 ⁻⁴	0.00313	0.50
	<i>CYP2C9</i> *3 (rs1057910)	-11.1%	-15.1%, -6.9%	3.72 × 10 ⁻⁵	0.00108	0.53
	<i>SLCO2B1</i> c.935G>A (rs12422149)	-5.4%	-8.9%, -1.7%	0.0178	0.516	0.54
	<i>SLCO2B1</i> c.1457C>T (rs2306168)	7.9%	1.9%, 14.2%	0.0289	0.837	0.55

BSA, body surface area; AUC_{0-∞}, area under the plasma concentration-time curve from 0 h to infinity

CI, confidence interval; SNV, single nucleotide variation

*Per 10% increase in BSA or variant allele copy